Ad-hoc announcement pursuant to Article 17 of the Regulation (EU) No. 596/2024
Gräfelfing, July 24, 2025 – FUTRUE GmbH informed PharmaSGP Holding SE (ISIN: DE000A2P4LJ5) today that it holds more than 95% of the shares in PharmaSGP Holding SE in the meaning of Section 327a of the German Stock Corporation Act (AktG).
Furthermore, today, FUTRUE GmbH submitted a request to PharmaSGP Holding SE pursuant to Section 327a of the German Stock Corporation Act (AktG) that the general meeting of PharmaSGP Holding SE shall pass a resolution on the transfer of the shares held by the remaining shareholders of PharmaSGP Holding SE to FUTRUE GmbH in return for an appropriate cash compensation (squeeze-out).
As also mentioned in the ad hoc announcement by PharmaSGP Holding SE on June 10, 2025, FUTRUE GmbH announced its intention to carry out a squeeze-out of the minority shareholders of PharmaSGP Holding SE within the meaning of Section 327a of the German Stock Corporation Act (AktG) (in conjunction with Section 62 (5) of the German Transformation Act (UmwG), if applicable) already in the context of the publication of its decision to make a public delisting tender offer to the shareholders of PharmaSGP Holding SE on June 10, 2025.
The amount of the cash compensation under the squeeze-out is yet to be determined; it will be communicated by FUTRUE GmbH once the necessary valuation of PharmaSGP Holding SE has been completed. Thereafter, in accordance with statutory provisions, PharmaSGP Holding SE will decide upon convening an extraordinary general meeting to resolve upon the transfer resolution.
No comments:
Post a Comment